{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-040024","form_type":"8-K","ticker":"MLYS","cik":"0001933414","company_name":"Mineralys Therapeutics, Inc.","filed_at":"2026-06-03T10:02:29+00:00","discovered_at":"2026-06-03T10:10:00.257454+00:00","generated_at":"2026-06-03T10:11:21.519349+00:00","sec_items":["1.01","2.03"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Mineralys terminates lorundrostat royalties, secures up to $500M debt facility","bullets":["Amended Tanabe license: $200M one-time payment; royalties eliminated; license perpetual; up to $365M in milestones remain.","Secured $500M senior secured loan; $100M drawn; further tranches tied to FDA approval and net sales.","Loan matures 2031; interest SOFR+5.5% (floor 3.25%); secured by all assets including IP.","Change of control would accelerate $100M new milestone payments."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-040024","json":"https://secwatch.observer/filing/0001628280-26-040024.json","markdown":"https://secwatch.observer/filing/0001628280-26-040024.md","text":"https://secwatch.observer/filing/0001628280-26-040024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1933414/000162828026040024/0001628280-26-040024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1933414/000162828026040024/mlys-20260602.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T10:11:21.519349+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a9f3a5b2409f36254c702fad6c4aa1204cf790b7","claim":"Mineralys Therapeutics, Inc. entered into Senior Secured Term Loan Agreement with BioPharma Credit PLC valued at Up to $500,000,000 in term loans (effective 2026-06-02).","evidence_excerpt":"On June 2, 2026 (the “Closing Date”), the Company entered into a senior secured term loan agreement (the “Loan Agreement”) with BioPharma Credit PLC, as collateral agent (the “Agent”), and each of BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP, which are funds managed by Pharmakon Advisors, LP, as lenders.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1933414/000162828026040024/0001628280-26-040024-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"BioPharma Credit PLC"},{"label":"Value","value":"Up to $500,000,000 in term loans"},{"label":"Effective","value":"2026-06-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}